PERKINELMER, INC.
$NYSE:PKI
55 watching
PERKINELMER, INC.
$NYSE:PKI
55 watching

PerkinElmer's T-Cell Select reagent kit gets FDA approval for automation of T-SPOT.TB test

Trending News

PerkinElmer's T-Cell Select reagent kit has been approved by the US Food and Drug Administration for use in automating the company's T-SPOT.TB test workflow. The kit is designed to reduce hands-on time for laboratory personnel and lower overall costs. In a press release, the...

more

PerkinElmer gets FDA approval for T-Cell Select kit to automate TB test

  • PerkinElmer's (NYSE:PKI) Oxford Immunotec said that the U.S. Food and Drug Administration (FDA) approved the use of T-Cell Select reagent kit for automation of its T-SPOT.TB test workflow.
  • The T-Cell Select reagent kit...

more

PerkinElmer, Inc. (PKI) Presents at Baird's 2022 Global Healthcare Conference (Transcript)

PerkinElmer, Inc. (PKI)

Baird’s 2022 Global Healthcare Conference

September 13, 2022 10:50 AM ET

Company Participants

Prahlad Singh - CEO

Conference Call Participants

Tom Peterson -...

more

PerkinElmer: Focusing, Appealing

Towards the end of February, I concluded that there was a solid diagnosis for PerkinElmer (PKI) as it has seen a real boom following the pandemic. The company has seen strong "organic" performance, as I saw no reason to alter that stance.

Some...

more

PerkinElmer downgraded to hold at Stifel on CFO departure

  • Stifel has downgraded PerkinElmer (NYSE:PKI) from buy to hold following the recent announcement that Jamey Mock is leaving as the company's CFO.
  • The firm also reduced its price target to $170 from $190 (~13% upside...

more

PerkinElmer names new CFO as Jamey Mock joins Moderna

  • PerkinElmer (NYSE:PKI) announced Wednesday the departure of senior vice president and chief financial officer Jamey Mock as he joins Moderna (MRNA) as its finance chief.
  • The Board of healthcare diagnostics company,...

more
120.58 -1.41%
USD, PERKINELMER, INC.
PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments: diagnostics, which includes immunodiagnostics, reproductive health, and applied genomics, and discovery and analytical solutions, composed of life science, industrial, environmental, and food applications. PerkinElmer offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See more
Trending Topics
#HODL
1 Discussion
#MetaWealth
1 Discussion
#STEPNtothemoon
1 Discussion

All statements, views or opinions expressed here are the personal views of our users. They do not represent nor should they be construed as representing our statements, views or opinions. For the avoidance of doubt, any such statements, views or opinions are not and shall not be construed as financial advice.

Investing Made Smarter, Faster, Easier for Everyone